Xiumeile has sold the world's number one for 7 consecutive years. The potential market space is huge (with stocks)

What is the best medicine in the world? Is the plate blue root that 1.3 billion people often drink when they catch a cold? Or is it the red Gleevec in "I am not a drug god"? The answer is a drug that most people are not familiar with - Humira (Chinese name "Xiu Meile"). The product is a variety of international pharmaceutical giant AbbVie (Aibowei), its latest published 2018 financial report shows that Xiu Meile's 2018 sales of 134.46 billion yuan, set a record annual sales of a single drug. Since 2012, Xiu Meile has been ranked first in the global drug sales rankings.

The main name of Xia Mei Le is “Adalimumab Injection”. The reason why it has been ranked first in the world for 7 consecutive years is called “King of Medicine”. The key reason is that it can treat many diseases, and most of these diseases are A condition that is difficult to treat. Since its listing, it has been approved for the treatment of 14 diseases including rheumatoid arthritis, ankylosing spondylitis and psoriasis in the United States and the European Union. It is mainly targeted at rheumatoid arthritis and mandatory spondylitis, which are currently two diseases that are more common in the world and are more difficult to cure. At present, the total number of patients with rheumatoid arthritis and mandatory spondylitis in China is about 10 million, and the potential market space is huge.

In the A-share company:

Jingfeng Pharmaceutical: The wholly-owned subsidiary Shanghaifengfeng Pharmaceutical has its own research and development technology of adalimumab injection (recombinant human anti-TNF-a monoclonal antibody injection).

Hisun Pharmaceutical: The application for the listing of adalimumab injection has been submitted to the State Drug Administration.

Hualan Bio: Participating company Hualan Genetic Engineering Co., Ltd. has obtained the clinical trial approval for adalimumab injection.